A detailed history of Freestone Grove Partners LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 11,589 shares of REPL stock, worth $159,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,589
Holding current value
$159,696
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$10.54 - $14.93 $122,148 - $173,023
11,589 New
11,589 $140 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $679M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.